NEW YORK (GenomeWeb News) – Investment bank Cowen and Co. has downgraded Hologic's stock from Outperform to Market Perform and lowered its price target on the shares.

The bank cited growth headwinds for Hologic's NovaSure, ThinPrep, and legacy 2D mammography sales, as well as Gen-Probe pricing pressures. It said that, overall, the positives for the firm are not occurring quickly enough to offset these headwinds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.